Tübingen

BioFlux System Used in Key Studies to Identify Causes and Treatments of Blood Clots Related to COVID-19

Retrieved on: 
Thursday, January 27, 2022
COVID-19, University, Risk, Tübingen, Tyrosine-protein kinase SYK, Camp, Patient, Coagulation, Preprint, Thrombosis, Cardiovascular disease, Research, List of life sciences, Respiratory disease, University of Tübingen, Incidence, Drug discovery, BioRxiv, Time-invariant system, Inflammation, Teaching hospital, Iloprost, Pharmaceutical industry

Although predominantly a respiratory disease, COVID-19 has been shown to cause a range of responses, including adverse effects on the cardiovascular system.

Key Points: 
  • Although predominantly a respiratory disease, COVID-19 has been shown to cause a range of responses, including adverse effects on the cardiovascular system.
  • Both papers relied on the BioFlux system to assess platelet function in COVID-19 patients.
  • Used in more than 500 labs globally, the BioFlux system is available in a variety of configurations to meet the application requirements of any laboratory.
  • Systems are available with a range of capabilities and throughputs and are used in basic research through drug discovery and diagnostic development.

DGAP-News: CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R)

Retrieved on: 
Wednesday, June 30, 2021
CureVac, Tübingen, Pharmaceutical companies, Gerd Greune, Health care

CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mlbe to Lead Accelerated Development of The RNA Printer(R)

Key Points: 
  • CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mlbe to Lead Accelerated Development of The RNA Printer(R)
    The issuer is solely responsible for the content of this announcement.
  • Dr. Greune joins CureVac with extensive experience in the global pharmaceutical industry, including manufacturing of vaccines and fill & finish of biologics.
  • "On behalf of the Supervisory Board I would like to welcome Dr. Greune to the Management Board.
  • "I would like to thank Dr. von der Mlbe for his service on the CureVac Management Board.

DGAP-News: CureVac Appoints Klaus Edvardsen as Chief Development Officer

Retrieved on: 
Wednesday, June 2, 2021
CureVac, Tübingen, Health care, Health, Pharmaceutical companies, Merck Group, CVac, Ingmar Hoerr, CVnCoV, CureVac, CVNCOV, CUREVAC

TBINGEN, Germany / BOSTON, USA - June 2, 2021 - CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Klaus Edvardsen, MD, PhD, as Chief Development Officer.

Key Points: 
  • TBINGEN, Germany / BOSTON, USA - June 2, 2021 - CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Klaus Edvardsen, MD, PhD, as Chief Development Officer.
  • "We are very happy to welcome Dr. Edvardsen to the CureVac leadership team," said Jean Stphenne, Chairman of the Supervisory Board of CureVac.
  • "We are very pleased that Klaus is joining us in highly dynamic times for the company," said Dr. Franz-Werner Haas, Chief Executive Officer of CureVac.
  • Dr. Edvardsen joins CureVac from Merck KGaA, where he led early- and late-stage global oncology development as a Senior Vice President and Head of Global Oncology Development.

DGAP-News: CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV

Retrieved on: 
Friday, February 12, 2021
RNA vaccines, Medical research, Medicine, Health sciences, Health, CureVac, Tübingen, COVID-19 vaccine, BioNTech, BioNTech, Draft:Zorecimeran

CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV

Key Points: 
  • CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV
    The issuer is solely responsible for the content of this announcement.
  • CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV
    TBINGEN, Germany/ BOSTON, USA - February 12, 2021 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced initiation of a rolling submission with the European Medicines Agency (EMA) for CVnCoV, the company's mRNA-based COVID-19 vaccine candidate, currently in late-stage clinical testing.
  • The process was initiated when the first data package consisting of CVnCoV pre-clinical data was submitted to EMA and passed the technical validation.
  • The rolling submission represents a time-optimized route to provide and review all necessary data needed for a potential market authorization during a public health emergency.

DGAP-News: CureVac and UK Government to collaborate on development of vaccines against SARS-CoV-2 variants

Retrieved on: 
Friday, February 5, 2021
Medicine, Medical specialties, Health care, CureVac, Tübingen, Medical research, Vaccine, Vaccine Taskforce, COVID-19 vaccine

"The UK Government and its Vaccines Taskforce (VTF) has been at the forefront of surveillance, vaccine development and delivery of vaccines for deployment during this pandemic.

Key Points: 
  • "The UK Government and its Vaccines Taskforce (VTF) has been at the forefront of surveillance, vaccine development and delivery of vaccines for deployment during this pandemic.
  • At CureVac, we believe we have the ability to quickly adapt our mRNA technology to address current variants and prepare for the emergence of new strains.
  • This collaboration is expected to bring to bear our significant combined forces to ensure vaccines keep winning against COVID-19."
  • The development of new vaccine candidates is strengthened by a partnership with the UK Government and its Vaccines Taskforce, which CureVac entered in February 2021.

DGAP-News: CureVac Announces Closing of $450 million Follow-on Public Offering of Common Shares

Retrieved on: 
Tuesday, February 2, 2021
Finance, Financial services, Companies, CureVac, Tübingen, Evercore, Kempen & Co, CVac, NASDAQ, UBS, Offering, Investment banking

TBINGEN, Germany / BOSTON, USA - February 2, 2021 - CureVac N.V. (Nasdaq: CVAC) ("CureVac" or the "Company"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today the closing of its follow-on public offering of 5,000,000 common shares, at a public offering price of $90.00 per common share, for total gross proceeds of approximately $450 million.

Key Points: 
  • TBINGEN, Germany / BOSTON, USA - February 2, 2021 - CureVac N.V. (Nasdaq: CVAC) ("CureVac" or the "Company"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today the closing of its follow-on public offering of 5,000,000 common shares, at a public offering price of $90.00 per common share, for total gross proceeds of approximately $450 million.
  • BofA Securities, Jefferies and Evercore ISI are acting as joint book-running managers for the offering.
  • UBS Investment Bank, Guggenheim Securities, Berenberg and Kempen & Co are acting as passive book-running managers for the offering.
  • CureVac had its initial public offering on the New York Nasdaq in August 2020.

DGAP-News: CureVac and Rentschler Biopharma Ramp up Manufacturing of COVID-19 Vaccine, CVnCoV

Retrieved on: 
Monday, February 1, 2021
Medicine, Medical research, Health care, Health sciences, CureVac, Tübingen, COVID-19 vaccine, Vaccine, LAUPHEIM, CVnCoV, CureVac, Rentschler Biopharma SE

CureVac and Rentschler Biopharma Ramp up Manufacturing of COVID-19 Vaccine, CVnCoV

Key Points: 
  • CureVac and Rentschler Biopharma Ramp up Manufacturing of COVID-19 Vaccine, CVnCoV
    The issuer is solely responsible for the content of this announcement.
  • Rentschler Biopharma is gearing up for largescale cGMP (Current Good Manufacturing Practice) production of the formulated mRNA for CVnCoV.
  • Rentschler Biopharma contributes to the manufacturing of active pharmaceutical ingredient, downstream processing and formulation of drug substance for the vaccine.
  • The companies entered into a collaboration in November 2020 with the set-up of dedicated production lines at the Rentschler Biopharma site in Laupheim, Germany.

DGAP-News: CureVac Announces Pricing of $450 million Follow-on Public Offering of Common Shares

Retrieved on: 
Thursday, January 28, 2021
CureVac, Tübingen, Initial public offering, Finance, Financial markets, Stock market, Follow-on offering, CVac, NASDAQ

TBINGEN, Germany/ BOSTON, USA - January 28, 2021 - CureVac N.V. (Nasdaq: CVAC) ("CureVac" or the "Company"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today the pricing of its follow-on public offering of 5,000,000 common shares at a public offering price of $90.00 per common share, for total gross proceeds of approximately $450 million.

Key Points: 
  • TBINGEN, Germany/ BOSTON, USA - January 28, 2021 - CureVac N.V. (Nasdaq: CVAC) ("CureVac" or the "Company"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today the pricing of its follow-on public offering of 5,000,000 common shares at a public offering price of $90.00 per common share, for total gross proceeds of approximately $450 million.
  • In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 750,000 common shares at the public offering price, less underwriting discounts and commissions.
  • All of the common shares are being offered by CureVac.
  • CureVac had its initial public offering on the New York Nasdaq in August 2020.

DGAP-News: CureVac Announces Proposed Public Offering of Common Shares

Retrieved on: 
Monday, January 25, 2021
Finance, Money, Financial services, CureVac, Tübingen, Corporate finance, Stock market, Initial public offering, Evercore, Public offering, Kempen & Co, Underwriting

TBINGEN, Germany/ BOSTON, USA - January 25, 2021 - CureVac N.V. (Nasdaq: CVAC) ("CureVac" or the "Company"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today that it intends to offer and sell in an underwritten public offering 5,000,000 common shares.

Key Points: 
  • TBINGEN, Germany/ BOSTON, USA - January 25, 2021 - CureVac N.V. (Nasdaq: CVAC) ("CureVac" or the "Company"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today that it intends to offer and sell in an underwritten public offering 5,000,000 common shares.
  • In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 common shares at the public offering price, less underwriting discounts and commissions.
  • BofA Securities, Jefferies and Evercore ISI are acting as joint book-running managers for the proposed offering.
  • UBS Investment Bank, Guggenheim Securities, Berenberg and Kempen & Co are acting as the passive book-running managersfor the proposed offering.

DGAP-News: CureVac : CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV

Retrieved on: 
Thursday, January 7, 2021
Companies, Health care, Health, CureVac, Tübingen, Medical research, COVID-19 vaccine, Bayer, Vaccine, Bayer, CureVac

Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac's COVID-19 vaccine candidate CVnCoV.

Key Points: 
  • Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac's COVID-19 vaccine candidate CVnCoV.
  • "We are very happy to join forces with Bayer, whose expertise and infrastructure will help us make our vaccine candidate CVnCoV even more rapidly available to as many people as possible," said Dr. Franz-Werner Haas, Chief Executive Officer of CureVac.
  • CureVac is currently expanding its partner network for the development, production and distribution of its vaccine candidate.
  • Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world.